FORGOTTEN HISTORY: Beigene - Caught on Camera

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

BeOne Medicines Ltd. (NASDAQ:ONC) (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy.

Benzinga · Aug 29, 2025

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BeiGene (NASDAQ:BGNE) in the last three months.

Benzinga · Dec 3, 2024

Why Is BeiGene Stock Trading Higher On Wednesday?

BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivotal Phase 3 trials.

Benzinga · Nov 27, 2024

Where BeiGene Stands With Analysts

Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:

Benzinga · May 9, 2022

Recap: BeiGene Q1 Earnings

  BeiGene (NASDAQ:BGNE) reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Earnings BeiGene beat estimated earnings by 10.36%, reporting an EPS of $-4.24 versus an estimate of $-4.73.

Benzinga · May 5, 2022

InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing

Key Takeaways:

Benzinga · Apr 19, 2022

BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study

BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Benzinga · Apr 11, 2022

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Benzinga · Apr 11, 2022

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national agencies would let most Chinese firms keep their U.S.…

Benzinga · Apr 1, 2022

Analyst Ratings For BeiGene

Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Mar 17, 2022